CA-074: Selective Cathepsin B Inhibitor for Cancer and Neurodegeneration Research

Executive Summary: CA-074 is a highly selective inhibitor of cathepsin B, a lysosomal cysteine protease implicated in cancer metastasis, neurotoxicity, and immune modulation. Its low nanomolar inhibition constant (Ki) enables potent, target-specific blockade of cathepsin B activity with minimal off-target effects on related cathepsins H and L. Recent evidence demonstrates that cathepsin B release following MLKL-mediated lysosomal membrane permeabilization is critical for necroptosis execution in human cells (Liu et al., 2023). Chemical inhibition of cathepsin B with agents such as CA-074 confers protection against necroptotic cell death in established in vitro models. CA-074’s high solubility, stability profile, and low cytotoxicity at relevant concentrations make it a preferred reagent for dissecting cathepsin B-driven mechanisms in disease models (APExBIO).

Biological Rationale

Cathepsin B is a lysosomal cysteine protease abundant in mammalian cells. It participates in protein turnover, antigen processing, apoptosis, and regulated necrosis (necroptosis) (Liu et al., 2023). During necroptosis, MLKL polymerization triggers lysosomal membrane permeabilization (LMP), resulting in rapid cytosolic release of cathepsin B. This protease then cleaves essential cellular proteins, driving cell death. Cathepsin B overactivity has been causally linked to tumor invasion, metastasis, and neurodegenerative processes. Selective inhibition of cathepsin B is thus considered a rational approach to interrogate its roles in proteolytic cascades underlying cancer progression, neurotoxicity, and immune response modulation (see also).

Mechanism of Action of Cathepsin B inhibitor CA-074

CA-074 is a small molecule that binds irreversibly to the active site of cathepsin B, blocking its proteolytic function (APExBIO). The compound exhibits a Ki of 2–5 nM for cathepsin B, indicating strong affinity and efficient inhibition under physiological conditions. CA-074 shows high selectivity, with much weaker inhibition of cathepsins H and L (Ki = 40–200 μM). By targeting the cysteine residue in the catalytic domain, CA-074 prevents substrate cleavage and downstream proteolytic events essential for cell death and tissue invasion. This selectivity allows researchers to attribute phenotypic effects specifically to cathepsin B inhibition, avoiding confounding interference with other proteases (further details).

Evidence & Benchmarks

• Induction of necroptosis in human HT-29 cells leads to lysosomal membrane permeabilization and cytosolic release of cathepsin B, as visualized by live-cell imaging (Liu 2023, DOI:10.1038/s41418-023-01237-7).
• Chemical inhibition or knockdown of cathepsin B protects cells from necroptosis, confirming its essential role in cell death execution (Liu 2023, DOI).
• CA-074 exhibits potent inhibition of cathepsin B (Ki = 2–5 nM), with significantly reduced activity toward cathepsins H/L (Ki = 40–200 μM) (APExBIO, product page).
• In vivo, CA-074 reduces breast cancer metastasis to bone and lung in 4T1.2 tumor-bearing mouse models, indicating efficacy in translational settings (CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis).
• In cell culture, CA-074 at 10 mM is non-cytotoxic to human umbilical vein endothelial cells (HUVECs) (APExBIO).

This article extends the mechanistic context of CA-074: Advanced Cathepsin B Inhibition in Necroptosis and Cancer by providing updated evidence from recent necroptosis studies and clarifies the selectivity benchmark compared to standard protease inhibitors.

Applications, Limits & Misconceptions

CA-074 is widely implemented in:

• Mechanistic studies of necroptosis in cancer and neurodegeneration, where cathepsin B is implicated in cell death pathways.
• Dissecting the role of lysosomal proteases in antigen processing, apoptosis, and immune cell polarization (Th2 to Th1 switching).
• Translational models of tumor metastasis inhibition, especially in 4T1.2 breast cancer and neurotoxicity paradigms (see our strategic guidance article).

Common Pitfalls or Misconceptions

• CA-074 does not inhibit serine or aspartic proteases; it is selective for cysteine proteases, primarily cathepsin B.
• High concentrations in cell-based assays may affect off-target cysteine proteases; use recommended doses (nanomolar to low micromolar).
• It is not effective against all forms of cell death; specifically, it targets lysosomal cathepsin B-dependent pathways, not classical apoptosis or pyroptosis.
• Stability is optimal at -20°C; solutions are recommended for short-term use only due to potential hydrolysis in aqueous media.
• CA-074 is not a therapeutic drug but a tool compound for research; in vivo efficacy depends on model-specific pharmacokinetics and delivery.

Workflow Integration & Parameters

CA-074 (SKU A1926) from APExBIO is supplied as a small molecule suitable for in vitro and in vivo research. Solubility is ≥19.17 mg/mL in DMSO, ≥31.3 mg/mL in ethanol, and ≥5.91 mg/mL in water (with ultrasonic assistance) (APExBIO). For stability, stock solutions should be stored at -20°C and protected from light; solutions are best prepared fresh for experiments. Typical working concentrations range from 10 nM to 10 μM for cell culture assays, with minimal cytotoxicity at up to 10 mM in HUVECs. In vivo dosing in mouse models should be optimized based on tissue distribution and target engagement. CA-074 is shipped on blue ice to maintain compound integrity.

For comprehensive workflows targeting cathepsin B in metastasis, neurotoxicity, or immune modulation, refer to Strategic Inhibition of Cathepsin B: Mechanistic Insights. This article extends those discussions by integrating new necroptosis data and solubility benchmarks.

Conclusion & Outlook

CA-074 represents a gold-standard, selective cathepsin B inhibitor for mechanistic and translational research in oncology, neurobiology, and immunology. Its nanomolar potency, high selectivity, and robust performance in cell and animal models make it an indispensable tool for dissecting proteolytic cascades underlying necroptosis and metastasis. APExBIO provides CA-074 (A1926) with validated purity and handling protocols. Ongoing research continues to refine dosing strategies for emerging applications, including regulated cell death and immune modulation. For technical specifications and ordering, visit the Cathepsin B inhibitor CA-074 product page.